Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability

Abstract

Objective:

Short-term clinical trials have demonstrated the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD). This study examined long-term safety and tolerability of pregabalin in patients with GAD, social anxiety disorder (SAD), or panic disorder (PD).     

Attention deficit hyperactivity disorder in the European adult population: prevalence,disease awareness,and treatment guidelines

Abstract

Background:

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobiological disorder with childhood onset and persistence into adolescence and adulthood.     

Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine

Abstract

Background:

Attention-deficit/hyperactivity disorder (ADHD) and substance use disorder are often comorbid in adults. The effects of ADHD treatment on comorbid alcohol use disorder have not been extensively studied.     

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

Abstract

Objective:

The primary objective of this study was to evaluate the safety and tolerability of the investigational drug vortioxetine (Lu AA21004) in the long-term treatment of patients with major depressive disorder.     

Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders

Abstract

Objective:

This post hoc analysis examined efficacy and tolerability of open-label desvenlafaxine in patients with major depressive disorder switched from blinded placebo, venlafaxine extended release (ER), or desvenlafaxine.     

Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review

Abstract

Objectives:

Tuberous sclerosis complex (TSC) is a progressive genetic disorder characterized by pervasive benign tumor growth. We sought to assess the current understanding of burden of TSC-related neurological manifestations.     

Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study

Abstract

Objective:

To examine the predictors of duloxetine monotherapy versus other antidepressants among patients with major depressive disorder (MDD) in the Veterans Health Administration (VHA).     

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD

Abstract

Objective:

This study measured the effects of atomoxetine HCl on high-risk behaviors and health-related quality of life in adolescents with attention-deficit/hyperactivity disorder (ADHD), using a subgroup analysis of data from a previous clinical trial.     

HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system

Abstract

Objective:

To evaluate the impact of methylphenidate transdermal system (MTS) on health-related quality of life (HRQL) and medication satisfaction in children with attention-deficit/hyperactivity disorder (ADHD) as well as to identify potential moderators of HRQL and medication satisfaction.     

Low prevalence of hyponatremia codification in departments of internal medicine and its prognostic implications

Abstract

Objective:

Hyponatremia is the most frequent ionic disorder among ambulatory and hospitalized populations. The aim of the study is to describe the profile of patients admitted to internal medicine departments of Spanish hospitals with a diagnostic codification of hyponatremia in their discharge sheets.     

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity

Abstract

Objective:

To examine the impact of baseline severity on lisdexamfetamine dimesylate (LDX) efficacy in a long-term study of adults with attention-deficit/hyperactivity disorder (ADHD).     

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study

Abstract

Objective:

Painful physical symptoms are common in patients with major depressive disorder (MDD) and can negatively affect patient outcomes. Duloxetine has demonstrated efficacy in treating MDD and other certain painful conditions; this study specifically evaluated patients with both MDD and MDD-associated pain.     

Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands

Abstract

Objective:

To evaluate the number of patients reaching stable treatment with a stimulant (methylphenidate or dexamphetamine) or non-stimulant (atomoxetine) attention-deficit/hyperactivity disorder (ADHD) medication approved for use in the Netherlands, and the time to treatment stabilization among children and adolescents aged 6–17 years.     

Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder

Abstract

Objective:

Treatment-resistant depression (TRD) imposes substantial cost from the perspective of employers. The objective of this study was to assess direct healthcare costs and indirect (disability and medical-related absenteeism) costs associated with TRD compared with non-treatment-resistant major depressive disorder (MDD).     

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms

Abstract

Objective:

Painful physical symptoms are common in patients with major depressive disorder (MDD) and may predict poorer treatment outcomes. Duloxetine has demonstrated efficacy in treating both MDD and certain other painful conditions. This randomized, double-blind clinical trial assessed the effects of duloxetine in patients with both MDD and MDD-associated physical pain.     

Improving the design of maintenance studies for bipolar disorder

Abstract

Background:

In contrast to the trial design of acute mania studies, there is no standard design for bipolar maintenance studies. Over the past 15 years, the design of monotherapy maintenance studies in bipolar disorder has evolved significantly, but recent study designs continue to differ in important ways.     

Development of a family functioning scale for major depressive disorder

Abstract

Objective:

To better understand depression’s impact on family functioning from the perspectives of patients with major depressive disorder (MDD) and their partners; to develop and test patient and partner versions of a new self-reported measure, the Depression and Family Functioning Scale (DFFS), for use in clinical trials.     

Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension

Abstract

Background:

Pulmonary arterial hypertension (PAH) is a rare, progressive lung disorder that impairs performance of daily activities and quality of life (QoL), leading to right heart failure and death. Treatment options include prostanoids, endothelin antagonists, and phosphodiesterase type 5 inhibitors (e.g., tadalafil). Currently there is no cure for PAH, but tadalafil has improved exercise capacity in these patients.     

Treatment adherence and persistence with duloxetine,venlafaxine XR,and escitalopram among patients with major depressive disorder and chronic pain-related diseases

Abstract

Objective:

Chronic pain is prevalent in patients with major depressive disorder (MDD). This study compared adherence and persistence rates among MDD patients with comorbid chronic pain-related diseases (CPD, including fibromyalgia, diabetes with neurological manifestations, osteoarthritis, low back pain, and headache) for three antidepressants: duloxetine, venlafaxine XR, and escitalopram.